What is the prevalence of posterior subscapular cataract in the elderly population in a specific geographic location?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Posterior Subcapsular Cataract

The prevalence of posterior subcapsular cataract (PSC) in the general elderly population is approximately 2-3% based on national epidemiologic data, though this varies significantly by underlying risk factors and geographic UV-B exposure.

Population-Based Prevalence Data

The most comprehensive population-based estimate comes from the 1971-1972 National Health and Nutrition Examination Survey, which identified 18 cases of isolated PSC among a screened population, representing a relatively small proportion compared to cortical (n=55) and nuclear cataracts (n=104) 1. This suggests PSC accounts for roughly 10% of age-related cataracts in the general population.

Geographic and Environmental Considerations

Geographic location significantly impacts PSC prevalence through UV-B radiation exposure, though this effect is less pronounced for PSC compared to cortical cataracts 1. The specific location you're inquiring about would influence prevalence based on:

  • UV-B radiation intensity: Higher ambient UV-B counts increase risk, with a relative risk of 3.6 for high versus low UV-B exposure areas, though this association is stronger for cortical cataracts 2, 1
  • Rural versus urban residence: Shows minimal association with PSC specifically 1

Clinical Context and Risk Stratification

PSC prevalence varies dramatically based on underlying conditions rather than geography alone:

High-Risk Populations

  • Diabetic patients: 6.6-fold increased risk compared to non-diabetics 1
  • Steroid users: Confirmed significant association 2, 3
  • Hereditary retinal degenerations: 41% prevalence in patients with retinitis pigmentosa and related conditions, with highest rates in autosomal dominant RP 4
  • Atopic individuals: 30.6% of PSC cases had coexisting atopy 3
  • Hypertensive patients: 2.2-fold increased risk for systolic BP 160 mmHg versus 120 mmHg 1

Moderate-Risk Populations

  • Myopic patients: Common association with vacuolar-type PSC 3
  • History of uveitis or trauma: Established risk factors 3

Age and Demographic Patterns

Peak prevalence occurs in the 41-50 year age group for PSC, which is notably younger than nuclear or cortical cataracts 3. This contrasts with nuclear cataracts, which show a relative risk of 38.6 for age 70 versus 50 years 1.

Important Clinical Caveats

  • PSC accounts for 40% of surgical cataract cases despite lower overall prevalence, because it causes disproportionate visual disability due to its central location 2
  • 87% of PSC patients have reduced visual acuity, 76% report glare, and 46% have decreased contrast sensitivity 3
  • Genetic factors play minimal role in PSC (heritability only 4%, not statistically significant), unlike cortical cataracts which show 24% heritability 5
  • 32.5% of PSC cases are of unknown etiology even after thorough evaluation 3

Morphologic Considerations

When PSC is present, expect the following distribution 3:

  • Vacuolar type: 45% (most common in myopia, diabetes, RP, trauma)
  • Mixed type: 39.4% (most common in steroid use, atopy, uveitis, idiopathic)
  • Solid type: 15.6% (seen with myopia, diabetes, glaucoma)

Without knowing the specific geographic location and population characteristics (diabetes prevalence, steroid use patterns, UV-B exposure levels), a general estimate of 2-3% prevalence in unselected elderly populations is reasonable, with substantially higher rates (10-40%) in high-risk subgroups.

Related Questions

How can I protect my eyes when my left eye has already developed a posterior subcapsular (PSC) cataract?
Does the development of a posterior subcapsular cataract (PSC) in my right eye indicate weaker left brain function or impaired function of the left side of my body?
What is the pathophysiology of posterior subcapsular cataract?
What is the recommended management for posterior subcapsular cataract (PSC) and its impact on vision and quality of life?
What is posterior subcapsular cataract (PSC) and its impact on vision and quality of life?
What is the recommended prophylaxis for patients at moderate to high risk of developing deep vein thrombosis (DVT), such as those hospitalized for surgery, trauma, or with acute medical conditions?
What is the likely diagnosis for an adult patient presenting with synovitis of the 4th and 5th carpometacarpal (CMC) joints, marrow edema in the 4th and 5th metacarpophalangeal (MCP) joints, erosions, and a negative anti-cyclic citrullinated peptide (anti-CCP) test?
What is the recommended treatment for a 35-year-old female patient who developed hypothyroidism after her second delivery?
What is the appropriate dosage and administration of Direct Oral Anticoagulants (DOACs) for a patient with atrial fibrillation, deep vein thrombosis, or pulmonary embolism, considering factors like impaired renal function, body weight, and age?
What is the initial treatment for a patient with multiple sclerosis (MS) experiencing a flare without active demyelinating plaques?
For a patient with severe pain and significant inflammation (CRP > 300) at risk for hypotension, should Dilaudid (hydromorphone) or morphine be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.